
Zura Bio Limited: shareholders and insiders
Price
$0.93
November 20, 2026Market cap $119M
What Ploutos Investor adds for Zura Bio
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 78% since Oct 27, 2026, when the 10-Q these figures come from was filed ($4.27 then, $0.93 on Nov 20, 2026). The figures date from before that move.10-Q
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Jun 22, 2026, from their own Form 4 filings.
Bought on the market
$13M
1 person
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
- Feb 26, 2026Access Industries Holdings LLCKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Access Industries Holdings LLC | 2.00M | $6.25 | $13M | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 22, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by ZURA's officers and directors from 2023 up to November 21, 2025, 3 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- AI Biotechnology LLCwith 3 more personsClass A Ordinary Shares, par value $0.0001 per shareShare of class18.2%
- Athanor Capitalwith 1 more personClass A Ordinary Shares, par value $0.0001 per shareShare of class15.7%
- Suvretta Capital Management, LLCwith 2 more personsClass A Ordinary Shares, par value $0.0001 per shareShare of class9.90%
- Venrock Healthcare Capital Partners III, L.P.with 6 more personsClass A Ordinary Shares, par value $0.0001 per shareShare of class9.90%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| AI Biotechnology LLCwith 3 more personsClass A Ordinary Shares, par value $0.0001 per share | 18.2% | 19.70M | Mar 2, 20262 filings since May 28, 2025 | 13D/A | |
| Athanor Capitalwith 1 more personClass A Ordinary Shares, par value $0.0001 per share | 15.7% | 11.58M | Jan 27, 20262 filings since Jan 2, 2026 | 13D | |
| Suvretta Capital Management, LLCwith 2 more personsClass A Ordinary Shares, par value $0.0001 per share | 9.90% | 9.52M | May 12, 20262 filings since Feb 13, 2026 | 13G/A | |
| Venrock Healthcare Capital Partners III, L.P.with 6 more personsClass A Ordinary Shares, par value $0.0001 per share | 9.90% | 9.82M | May 15, 20263 filings since May 15, 2025 | 13G/A |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
AI Biotechnology LLC18.2%From the filing of May 28, 2025
The information set forth in Item 6 hereof is hereby incorporated herein by reference. The Reporting Persons who hold securities of the Issuer directly acquired those securities as an investment in the regular course of their businesses. The Reporting Persons may engage in discussions with management, the Issuer's board of directors, other stockholders of the Issuer and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of the Issuer. Dan Becker, Managing Director at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, currently serves on the board of directors of the Issuer. The Reporting Persons…
From the filing of May 28, 2025Athanor Capital15.7%From the filing of Jan 27, 2026
The securities reported herein were acquired by the Reporting Persons for investment purposes in the ordinary course of business. The Reporting Persons acquired the securities without the purpose or effect of changing or influencing the control of the Issuer and do not have any present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through 4(j) of Schedule 13D. The Reporting Persons may, from time to time, review their investment in the Issuer and may engage in discussions with management or the board of directors of the Issuer regarding the Issuer's business, operations and prospects, subject to applicable law. The Reporting Persons reserve…
From the filing of Jan 27, 2026
Fell to 5% or less (6)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+213%
- Millennium Mgmt (Englander)In the quarter+442%
- D.E. ShawIn the quarter
- Renaissance TechnologiesIn the quarter-84%
- AQR CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 939.8K | +213% | $3.9M | 0.00% |
| Millennium Mgmt (Englander) | 745.8K | +442% | $3.1M | 0.00% |
| D.E. Shaw | 43.8K | $200.0K | 0.00% | |
| Renaissance Technologies | 50.7K | -84% | $200.0K | 0.00% |
| AQR Capital | 12.7K | $100.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 5.50% of its shares outstanding were held short, -25.1% since the report before.
- Shares held short
- 7.02M
- 5.50%
- Since the report before9.37M on Sep 30, 2026
- -25.1%
- 1.5
- 4.78M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 20%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 461.9K
- Nov 15, 2023: Shares held short 171.2K
- Nov 30, 2023: Shares held short 173.0K
- Dec 15, 2023: Shares held short 215.9K
- Dec 29, 2023: Shares held short 436.9K
- Jan 12, 2024: Shares held short 352.9K
- Jan 31, 2024: Shares held short 328.5K
- Feb 15, 2024: Shares held short 383.1K
- Feb 29, 2024: Shares held short 358.2K
- Mar 15, 2024: Shares held short 330.0K
- Mar 28, 2024: Shares held short 628.3K
- Apr 15, 2024: Shares held short 428.4K
- Apr 30, 2024: Shares held short 400.5K
- May 15, 2024: Shares held short 721.4K
- May 31, 2024: Shares held short 569.7K
- Jun 14, 2024: Shares held short 643.4K
- Jun 28, 2024: Shares held short 710.1K
- Jul 15, 2024: Shares held short 1.79M
- Jul 31, 2024: Shares held short 3.44M
- Aug 15, 2024: Shares held short 4.02M
- Aug 30, 2024: Shares held short 663.3K
- Sep 13, 2024: Shares held short 849.7K
- Sep 30, 2024: Shares held short 1.86M
- Oct 15, 2024: Shares held short 1.88M
- Oct 31, 2024: Shares held short 1.75M
- Nov 15, 2024: Shares held short 4.96M
- Nov 29, 2024: Shares held short 5.16M
- Dec 13, 2024: Shares held short 5.01M
- Dec 31, 2024: Shares held short 4.95M
- Jan 15, 2025: Shares held short 4.99M
- Jan 31, 2025: Shares held short 4.88M
- Feb 14, 2025: Shares held short 5.13M
- Feb 28, 2025: Shares held short 5.23M
- Mar 14, 2025: Shares held short 5.31M
- Mar 31, 2025: Shares held short 5.37M
- Apr 15, 2025: Shares held short 2.59M
- Apr 30, 2025: Shares held short 2.49M
- May 15, 2025: Shares held short 2.51M
- May 30, 2025: Shares held short 3.08M
- Jun 13, 2025: Shares held short 2.67M
- Jun 30, 2025: Shares held short 1.16M
- Jul 15, 2025: Shares held short 585.9K
- Jul 31, 2025: Shares held short 534.4K
- Aug 15, 2025: Shares held short 544.6K
- Aug 29, 2025: Shares held short 425.3K
- Sep 15, 2025: Shares held short 458.1K
- Sep 30, 2025: Shares held short 2.05M
- Oct 15, 2025: Shares held short 2.62M
- Oct 31, 2025: Shares held short 2.72M
- Nov 14, 2025: Shares held short 2.57M
- Nov 28, 2025: Shares held short 2.54M
- Dec 15, 2025: Shares held short 2.60M
- Dec 31, 2025: Shares held short 2.85M
- Jan 15, 2026: Shares held short 3.01M
- Jan 30, 2026: Shares held short 3.85M
- Feb 13, 2026: Shares held short 4.08M
- Feb 27, 2026: Shares held short 4.74M
- Mar 13, 2026: Shares held short 5.11M
- Mar 31, 2026: Shares held short 5.75M
- Apr 15, 2026: Shares held short 6.15M
- Apr 30, 2026: Shares held short 6.97M
- May 15, 2026: Shares held short 6.24M
- May 29, 2026: Shares held short 6.22M
- Jun 15, 2026: Shares held short 5.87M
- Jun 30, 2026: Shares held short 9.24M
- Jul 15, 2026: Shares held short 10.25M
- Jul 31, 2026: Shares held short 10.51M
- Aug 14, 2026: Shares held short 11.44M
- Aug 31, 2026: Shares held short 11.10M
- Sep 15, 2026: Shares held short 9.34M
- Sep 30, 2026: Shares held short 9.37M
- Oct 15, 2026: Shares held short 7.02M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading43.3% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 43.3% of the shares in the reported trades were short sales, against 48.4% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 43.3%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 48.4%
- Change
- -5.1 pts
- Short sales a dayon average, of 4.83M shares
- 2.09M
- More than atof 3,666 US-listed companies, same days
- 28%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 52.9%
- Oct 15, 2026: Short sales 54.5%
- Oct 16, 2026: Short sales 64.5%
- Oct 19, 2026: Short sales 39.2%
- Oct 20, 2026: Short sales 29.2%
- Oct 21, 2026: Short sales 21.2%
- Oct 22, 2026: Short sales 49.9%
- Oct 23, 2026: Short sales 52.8%
- Oct 26, 2026: Short sales 59.5%
- Oct 27, 2026: Short sales 34.6%
- Oct 28, 2026: Short sales 39.4%
- Oct 29, 2026: Short sales 61.8%
- Oct 30, 2026: Short sales 67.9%
- Nov 2, 2026: Short sales 45%
- Nov 3, 2026: Short sales 43%
- Nov 4, 2026: Short sales 56.8%
- Nov 5, 2026: Short sales 57%
- Nov 6, 2026: Short sales 57.2%
- Nov 9, 2026: Short sales 56.1%
- Nov 10, 2026: Short sales 17.2%
- Nov 11, 2026: Short sales 23.5%
- Nov 12, 2026: Short sales 18.3%
- Nov 13, 2026: Short sales 8.4%
- Nov 16, 2026: Short sales 24.9%
- Nov 17, 2026: Short sales 47.7%
- Nov 18, 2026: Short sales 50.7%
- Nov 19, 2026: Short sales 40.6%
- Nov 20, 2026: Short sales 31.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.08%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.02%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
5 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 66
- Q4 2025: Managers 74
- Q1 2026: Managers 95
- Q2 2026: Managers 95
Institutional investors by quarter
The fund managers holding ZURA, quarter by quarter, from Q1 2023 to Q2 2025, 10 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 95 managers held 72.94M shares, worth $429M. During the quarter 25 opened a position, 26 closed one, 31 added and 19 trimmed.
The largest holders, Q2 2026
- Montanova CapitalIn the quarter+4.1%
- Venrock AdviserIn the quarter
- Mpm BioimpactIn the quarter
- JPMorgan ChaseIn the quarter-2.3%
- Great Point PartnersIn the quarter
- BraidwellIn the quarter-0.2%
- SirenIn the quarter
- BlackRockIn the quarter+690%
- Commodore CapitalIn the quarter
- Adage Capital Partners GpIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Montanova Capital | 9.44M | +4.1% | $56M |
| Venrock Adviser | 6.43M | $38M | |
| Mpm Bioimpact | 4.47M | $26M | |
| JPMorgan Chase | 4.35M | -2.3% | $25M |
| Great Point Partners | 4.22M | $25M | |
| Braidwell | 3.98M | -0.2% | $23M |
| Siren | 3.73M | $22M | |
| BlackRock | 3.61M | +690% | $21M |
| Commodore Capital | 3.25M | $19M | |
| Adage Capital Partners Gp | 2.75M | $16M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Zura Bio's filings show?
Who buys and sells is one part of Zura Bio's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have ZURA's insiders bought or sold?
From Jun 22, 2026 to Jun 22, 2026 Zura Bio's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold ZURA?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $3.9M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.